# Calciscon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calciscon

- Industry: Biotechnology
- Headquarters: Biel/Bienne, Switzerland
- Website: www.calciscon.com
- Total disclosed funding: $0.1M
- Latest round: Seed (Mar 26, 2014)
- Investors on record: 1

## About

Based in Switzerland, Calciscon AG operates as a diagnostic technology company focusing on innovative solutions for real-time monitoring of bone health, particularly through calcium level measurement systems.Calciscon AG, founded in 2013 and headquartered in Biel/Bienne, Switzerland, specializes in diagnostic solutions for the healthcare sector. The company is led by CEO Vincent Linder. It has completed 4 deals, with the most recent funding round occurring on January 11, 2023, raising EUR 2 million from investor Eureka-Eurostars, bringing the total amount raised to EUR 2 million.CALCISCON specializes in innovative diagnostic solutions that cater primarily to the healthcare sector. The company's core product offerings include advanced technology for real-time monitoring and analysis of bone health, particularly through its flagship device designed to measure calcium levels in the body. This technology addresses critical healthcare challenges related to bone density and metabolic health, serving medical professionals and patients who require precise monitoring of their calcium levels. The primary end users of these products include hospitals, clinics, and general practitioners across Europe, North America, and select regions in Asia. CALCISCON’s commitment to enhancing patient outcomes is reflected in its ongoing product development, aimed at facilitating better clinical decisions and improving overall health management.CALCISCON's revenue generation model is anchored in a B2B framework, where the company engages directly with healthcare institutions and practitioners who integrate their diagnostic tools into routine patient care. The transaction structure typically involves direct sales and potential partnership agreements with healthcare providers, allowing for bulk purchasing arrangements. Pricing plans for CALCISCON's flagship products reflect their advanced technological capabilities, ensuring they remain competitive while providing value to their clientele. The sales cycle includes training and support services, which are integral to the successful deployment of the company's products in clinical settings. This comprehensive approach fosters customer loyalty and encourages repeat business, solidifying CALCISCON's position in the healthcare diagnostic market.In January 2023, Calciscon AG raised EUR 2 million in venture funding from Eureka-Eurostars, which will support the development of new diagnostic products aimed at enhancing bone health monitoring. The company plans to launch these new offerings within the next 12 months. Additionally, Calciscon AG aims to expand its market presence into Asia and North America by the end of 2024, targeting healthcare facilities that require advanced diagnostic solutions.

## Funding rounds

- Seed, Mar 26, 2014, $0.1M — Venture Kick

## Investors

- Venture Kick (https://capitalatlas.ai/funds/venture-kick) — Seed